Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  6. News
  7. Summary
    MED   DE0006595101


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : MediClin AG: The demand for non-corona-induced medical and therapeutic measures has been increasing since mid-2021

07/30/2021 | 07:11am EDT
DGAP-News: MediClin AG / Key word(s): Half Year Results 
MediClin AG: The demand for non-corona-induced medical and therapeutic measures has been increasing since mid-2021 
2021-07-30 / 13:10 
The issuer is solely responsible for the content of this announcement. 
The demand for non-corona-induced medical and therapeutic measures has been increasing since mid-2021 
In the first months of 2021 - due to the 3rd wave of the corona pandemic - there was still a low number of referrals 
from acute clinics and a reluctance to make use of rehabilitation services. This led only to a hesitant increase in 
occupancy in the first half of 2021. The occupancy has increased somewhat more clearly since the middle of the year. 
Operating Group sales in the 1st half of 2021 above the previous year's value, but still below the pre-Corona level 
In the first half of 2021, MEDICLIN achieved Group sales of EUR 323.1 mill., which is EUR 0.4 mill. or 0.1% less than 
in the first half of 2020. At operating level, without benefits under the protective shield, Group sales increased by 
EUR 15.9 mill. or 5.4 % compared to the previous year's period. Compared to 2019 before the coronavirus pandemic, sales 
without benefits under the protective shield are still EUR 25.3 mill. or 7.6 % below the sales generated in the first 
half of 2019. 
As far as the Group operating result is concerned, at EUR -13.4 mill., it is EUR 4.6 mill. below the value of the first 
half of 2020 of EUR -8.8 mill. The result was impacted by an increase in raw materials and consumables used, mainly 
driven by higher demand and due to higher expenditure for hygiene and protective measures. Despite a decline in 
headcount, staff costs rose moderately. 
As of June 30, 2021, cash and cash equivalents amounted to EUR 95.6 mill. (December 31, 2020: EUR 100.4 million). The 
cash and cash equivalents as of the balance sheet date include subsidies and expected reimbursements under the corona 
protective shield and other measures in the amount of around EUR 66.5 mill. 
Although the number of people infected with Corona has fallen continuously since the end of the 3rd wave respective the 
end of April 2021 - they are currently increasing again slightly - nevertheless, the sales and earnings development for 
the year as a whole depends on the further development of the number of infections and protective shield benefits. The 
protective shield benefits will be significantly lower for the year 2021", comments Tino Fritz, CFO of MEDICLIN, on the 
expected further business development. MEDICLIN is currently assuming that capacity utilization at the level before 
Corona might not be achievable in the second half of 2021. 
Reporting of the segments 
In the post-acute segment, sales increased by EUR 4.2 mill. or 2.3%. Without taking protective shields benefits into 
account, sales increased by EUR 12.7 mill. or 7.4% in a half-year comparison. 
The acute segment shows a decline in segment sales of EUR 5.1 million or 4.0%. Without protective shield services, 
sales rose by EUR 3.6 million or 3.1%. In the other activities segment, sales in the nursing care business area 
amounted to EUR 8.2 mill., EUR 0.4 mill. above the previous year's figure. 
Competence in post-COVID and long-COVID treatments 
The interdisciplinary expertise that MEDICLIN has in the treatment of post-COVID and long-COVID patients is reflected 
in a significantly increasing demand. Pneumology experts work closely with experts in neurology, cardiology, psychiatry 
and psychosomatics. 
Innovative concepts in rehabilitation 
In addition to an offer for post-COVID and long-COVID patients, MEDICLIN is also increasingly taking care of other 
innovative concepts in rehabilitation. "It will be a particular challenge to adapt rehabilitation to changing 
demographic and social requirements with innovative performance-based concepts," said Dr. York Dhein, Member of the 
Management Board of MEDICLIN and responsible for this business segment, and added: "MEDICLIN has shown that we can 
quickly build up and implement knowledge in our company in the treatment of post- and long-COVID patients." 
Über die MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510) 
Zu MEDICLIN gehören 35 Kliniken, sieben Pflegeeinrichtungen und zehn Medizinische Versorgungszentren. Die Gruppe 
verfügt über rund 8.350 Betten/Pflegeplätze und beschäftigt rund 10.200 Mitarbeiter. In einem starken Netzwerk bietet 
MEDICLIN dem Patienten die integrative Versorgung vom ersten Arztbesuch über die Operation und die anschließende 
Rehabilitation bis hin zur ambulanten Nachsorge. Ärzte, Therapeuten und Pflegekräfte arbeiten dabei sorgfältig 
abgestimmt zusammen. Die Pflege und Betreuung pflegebedürftiger Menschen gestaltet MEDICLIN nach deren individuellen 
Bedürfnissen und persönlichem Bedarf. 
MEDICLIN   ein Unternehmen der Asklepios-Gruppe. 
2021-07-30 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:     English 
Company:      MediClin AG 
              Okenstraße 27 
              77652 Offenburg 
Phone:        +49 (0)781 488-326 
Fax:          +49 (0)781 488-184 
E-mail:       alexandra.muehr@mediclin.de 
Internet:     www.mediclin.de 
ISIN:         DE0006595101 
WKN:          659510 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1223058 
End of News   DGAP News Service 

1223058 2021-07-30

Image link: 

(END) Dow Jones Newswires

July 30, 2021 07:10 ET (11:10 GMT)

All news about MEDICLIN AG
07/30PRESS RELEASE : MediClin AG: The demand for non-corona-induced medical and thera..
07/30MEDICLIN AG : The demand for non-corona-induced medical and therapeutic measures..
06/11PRESS RELEASE : MediClin AG: Dr. Joachim Ramming becomes the new CEO of MEDICLIN
06/11MEDICLIN AG : Dr. Joachim Ramming becomes the new CEO of MEDICLIN
06/11MEDICLIN Aktiengesellschaft Announces Management Change
06/11MEDICLIN Aktiengesellschaft Announces Executive Changes
05/28PRESS RELEASE : MEDICLIN focuses on patient safety and innovative concepts in re..
05/28MEDICLIN : focuses on patient safety and innovative concepts in rehabilitation
05/03MEDICLIN Aktiengesellschaft Reports Earnings Results for the First quarter En..
05/03MEDICLIN AG : The effects of the coronavirus pandemic are burdening the business..
More news
Sales 2021 660 M 774 M 774 M
Net income 2021 -9,33 M -10,9 M -10,9 M
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 182 M 214 M 214 M
Capi. / Sales 2021 0,28x
Capi. / Sales 2022 0,26x
Nbr of Employees 7 498
Free-Float 12,3%
Duration : Period :
MEDICLIN AG Technical Analysis Chart | MED | DE0006595101 | MarketScreener
Technical analysis trends MEDICLIN AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,84 €
Average target price 5,55 €
Spread / Average Target 44,5%
Managers and Directors
Joachim Ramming Chairman-Management Board & CEO
Tino Marco Fritz Chief Financial Officer
Jan Liersch Chairman-Supervisory Board
J÷rg St÷rmer Head-Purchasing & Medical Technology
York Dhein Chief Operating Officer
Sector and Competitors